Outcome measures
TB, leprosy
ADVERSE EVENTS, LEPROSY, SECONDARY
The primary outcome will be the leprosy incidence rate ratio between contacts who received SDR-PEP and contacts who received BE-PEP, excluding those in arm 1 who received SDR-PEP because of not being eligible for BE-PEP due to age and/or weight restrictions. In a secondary analysis, we will calculate the incidence rate ratios at the village level between arms 1 and 2, including all participants irrespective of whether or not they received PEP.Other outcome measures will be the frequency of adverse events by PEP regimen and costing of both study arms, and serosurvey in 2026 quantitatively assessing anti-PLG-I IgM antibodies in a subset of villages. We will also report proportions of leprosy or TB patients with resistance to either of the study drugs and assess any trends if present. A cost-effectiveness of BE-PEP compared to SDR-PEP will be done if BE-PEP is shown to be more effective.